Skip to main content
. 2021 Mar 12;19(3):148. doi: 10.3390/md19030148

Figure 5.

Figure 5

LMF-HSFx reduces the insulin resistance in patients with NAFLD. The graph demonstrated the change from baseline of (A) AC, (B) HbA1c, (C) insulin, (D) HOMA-IR and (E) the insulin secretion index (beta cell function index) of patients with LMF-HSFx or placebo treatment. Significant reduction of AC, HbA1c change was observed at 3rd and 6th month in LMF-HSFx group (* p < 0.05, ** p < 0.01, compared with placebo). (D) The average HOMA-IR of placebo not LMF-HSFx group was higher than 3.5 at 6th month. (E) The increasing of beta cell function index in LMF-HSFx group during the 6 months.